Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

lure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achiev
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/lmsnqn/medical_equipment ) has announced ... Leasing - Global Strategic Business Report" report to ... markets for Medical Equipment Rental and Leasing in US$ ... US, Japan , Europe ... estimates and forecasts are provided for the period 2014 ...
(Date:4/17/2015)... DIEGO , April 17, 2015  Trovagene, ... diagnostics, announced today that clinical data presented at ... that its urine-based Precision Cancer Monitoring ℠ ... and monitoring of EGFR T790M mutations ... Detection of EGFR T790M Mutation in Urinary ...
(Date:4/17/2015)... 17, 2015 Research and Markets ( ... "Medical Oxygen Systems - Global Strategic Business Report" ... the worldwide markets for Medical Oxygen Systems in US$ ... Systems, Oxygen Cylinders & Regulators, and Oxygen Conserving Devices. ... Canada , Japan ...
Breaking Medicine Technology:Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2
... Care Pharmacy Alliance,s (LTCPA) recent study, "Measurement of Unused ... has been published in the September 2011 issue of ... American Society of Consultant Pharmacists. This is the first ... value of unused solid oral dosage from prescription drugs ...
... RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 ... LLY ) will present the latest ... Annual Meeting of the European Association for the ... 12-16. Study results evaluating the dipeptidyl peptidase-4 (DPP-4) ...
Cached Medicine Technology:LTCPA Study Quantifying Unused Medicare Part D Drugs in Skilled Nursing Facilities Published in The Consultant Pharmacist 2Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes 4Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes 5Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes 6
(Date:4/18/2015)... 18, 2015 In the past few ... of changes. , "We had to run maintenance on ... changes," said Jennifer Ramirez, the PR Director. "It disrupted ... say that we are back on track after having ... process of changing phone systems which has not allowed ...
(Date:4/18/2015)... York, NY (PRWEB) April 18, 2015 On ... Internal Security Threat Report , which they say, “exposes a ... how many new malware variants were introduced in 2014 - ... took for Zero Day threats to be identified and patched ... it is abundantly clear that doing business in a digital ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... , In a turbulent world, people may find themselves ... always be their first move, but some situations can be ...
(Date:4/18/2015)... 2015 French physician and gastronome Anthelme ... when he uttered, “Tell me what you eat, and ... to cope with stress or sadness has often been ... indicates otherwise. Data collected from their Emotional Eating ... emotional eating, but for different reasons. , Collecting data ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2
... February 20, at 10:00 a.m. ESTLA JOLLA, Calif., ... Board: CDXP) will host a teleconference on Friday, ... a fourth quarter business review and drug development ... M.D., M.B.A., will give the presentation and there ...
... language to do numbers, researcher explains , , FRIDAY, Feb. ... basic math and pre-verbal "number sense," but it,s the ... to take math to much higher levels, says a ... of psychology and neuroscience at Duke, studies how human ...
... Healthcare Associates,LLC, the Oregon-based obstetrics, gynecology, midwifery, maternal ... Welch, CNM, MSN, has,been honored by the American ... , Ms. Welch, who ... in Portland, received the honor in a recent ...
... Feb. 13 As the FDA and pharmaceutical ... and mitigation plans for extended release opioids, thousands ... have already discovered a resource that supports the ... Emerging Solutions in Pain ( www.emergingsolutionsinpain.com ) ...
... The following is from Betsy McCaughey, Ph.D., the author ... Obama Stimulus Plan."If Keith Olbermann of MSNBC could ... their merits, he wouldn,t be resorting to personal attacks on ... drug industry (2-12-2009). That,s not true.I am not paid ...
... highest ionized serum calcium 3 times more likely to die, ... A newly identified biomarker for fatal prostate cancer may help ... treatment for the disease. , Men whose levels of ... times more likely to die of prostate cancer than those ...
Cached Medicine News:Health News:Cordex Pharma Sets Fourth Quarter 2008 Program Update Call 2Health News:Cordex Pharma Sets Fourth Quarter 2008 Program Update Call 3Health News:College Kids and Monkeys About Equal on Math 2Health News:Women's Healthcare Associates Midwife Winner of American Academy of Nurse Practitioners State Award of Excellence 2Health News:Opioid Safety and Efficacy Web Resource for Clinicians Supports Education and Practice Needs 2Health News:Opioid Safety and Efficacy Web Resource for Clinicians Supports Education and Practice Needs 3Health News:Invitation to Keith Olbermann 2Health News:Researchers ID Biomarker for Fatal Prostate Cancer 2
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Central platform with integrated neck. ... platform utilizing an internal spring to ... use. Cutting Block fits into precision ... trephine blades sized 6.25 - 9.0mm. ...
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Medicine Products: